Wall Street Expects Intellia Therapeutics Stock to Climb 107%. Is That Too Optimistic?The Motley Fool • 06/23/23
Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit?The Motley Fool • 06/21/23
Intellia Therapeutics Stock Could Roar in the Next Bull Market. Here's Why.The Motley Fool • 06/19/23
Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)GlobeNewsWire • 06/11/23
Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of DirectorsGlobeNewsWire • 06/05/23
Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023GlobeNewsWire • 05/31/23
Are You Looking for a Top Momentum Pick? Why Intellia Therapeutics, Inc. (NTLA) is a Great ChoiceZacks Investment Research • 05/09/23
Wall Street Analysts Think Intellia Therapeutics, Inc. (NTLA) Could Surge 115.12%: Read This Before Placing a BetZacks Investment Research • 05/09/23
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/04/23
Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 05/04/23